Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ishvinder Grewal

Orthopaedic Trauma Dallas, TX Medical Doctor

NPI 1306498761 CMS profile 7176209

5201 Harry Hines Blvd, Dallas, TX 75235

Open in the dashboard

General payments

$43,324

334 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ishvinder Grewal of Dallas, TX is reported in the CMS Open Payments database as having received $43,324 across 334 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,546 65
2024 General $8,518 67
2023 General $4,438 63
2022 General $13,913 76
2021 General $6,019 40
2020 General $764 8
2019 General $2,126 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ishvinder Grewal
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Ishvinder Grewal were reported at $7,546. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Ishvinder Grewal Orthopaedic Trauma median Middle half National median
2019 $2,126 $1,475 $264–$6,401 $163
2020 $764 $596 $120–$4,020 $114
2021 $6,019 $919 $171–$4,697 $132
2022 $13,913 $1,547 $272–$7,240 $149
2023 $4,438 $1,330 $247–$5,875 $160
2024 $8,518 $1,288 $277–$6,797 $164
2025 $7,546 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $8,263 38 payments
  2. OsteoCentric Technologies, Inc. $6,955 37 payments
  3. Pylant Medical $6,407 49 payments
  4. Medical Device Business Services, Inc. $6,293 32 payments
  5. Stryker Corporation $3,988 24 payments
  6. Smith+Nephew, Inc. $3,619 30 payments
  7. DePuy Synthes Sales Inc. $2,814 69 payments
  8. Globus Medical, Inc. $1,808 10 payments
  9. MY01 Inc. $662 3 payments
  10. Baxter Healthcare $659 9 payments
  11. Other $1,857 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $18,631 55 payments
  2. Food and Beverage $16,750 270 payments
  3. Education $7,314 6 payments
  4. Grant $450 1 payment
  5. Entertainment $179 2 payments
Products named General payments · program years 2019–2025
  1. OsteoCentric 4.0 x 130mm LOCKING BONE SCREW FASTENER ST $6,797 36 payments
  2. NA Trauma $4,049 30 payments
  3. PRO $2,064 8 payments
  4. EVOS $1,796 12 payments
  5. TFN-Advance $1,610 15 payments
  6. TRIGEN $1,526 14 payments
  7. ANTHEM $1,390 5 payments
  8. NA Orthopedics $1,362 7 payments
  9. VA-LCP $1,181 28 payments
  10. TRIGEN InterTAN $691 5 payments
  11. Other $11,245 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

110

Median for Orthopedic Surgery: 203

Drug cost

$1,535

Median for Orthopedic Surgery: $1,433

Branded share of claims

43.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Monohydrate Generic 23 $567
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $291
Gabapentin Generic 15 $256
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $211
Methocarbamol Generic 24 $133
Ondansetron Odt Ondansetron Brand 15 $77

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$55,663

Medicare's payments for the services billed

Medicare patients

83

Average age 72

Services billed

181

46 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 36%
Osteoporosis 36%
Diabetes 33%
Chronic kidney disease 30%
Ischemic heart disease 27%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

334 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record